Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - PRESS RELEASE - ENZON PHARMACEUTICALS, INC. | ex99-1.htm |
UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
8-K
CURRENT
REPORT
Pursuant
to Section 13 or 15(d) of the
Securities
Exchange Act of 1934
Date
of report (Date of earliest event reported): November 9, 2009
ENZON
PHARMACEUTICALS, INC.
(Exact
Name of Registrant as Specified in Charter)
|
Delaware
|
0-12957
|
22-2372868
|
||
|
(State
or Other Jurisdiction ofIncorporation)
|
(CommissionFile
Number)
|
(IRS
Employer Identification No.)
|
|
685
Route 202/206, Bridgewater, NJ
|
08807
|
|
|
(Address
of Principal Executive Offices)
|
(Zip
Code)
|
Registrant's telephone number,
including area code: (908)
541-8600
|
Not
Applicable
|
||
|
(Former
Name or Former Address, if Changed Since Last Report)
|
Check
the appropriate box below if the Form 8-K filing is intended to simultaneously
satisfy the filing obligation of the registrant under any of the following
provisions (see General
Instruction A.2. below):
|
□
|
Written
communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|
|
■
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
|
□
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR
240.14d-2(b))
|
|
□
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR
240.13e-4(c))
|
Section
8 – Other Information
Item
8.01. Other Events.
On
November 9, 2009, Enzon Pharmaceuticals, Inc. issued a press release regarding
the sale of its specialty pharmaceutical business. A copy of the
press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and is
incorporated herein by reference.
Section
9 – Financial Statements and Exhibits
Item
9.01. Financial Statements and Exhibits.
|
Exhibit
No.
|
Exhibit
|
|
|
99.1
|
Enzon
Pharmaceuticals, Inc. press release, dated November 9,
2009.
|
SIGNATURES
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned hereunto
duly authorized.
Date: November
9, 2009
|
ENZON
PHARMACEUTICALS, INC.
|
||
|
By:
|
/s/
Jeffrey H. Buchalter
|
|
|
Name:
|
Jeffrey
H. Buchalter
|
|
|
Title:
|
President
and Chief Executive Officer
|
|
Exhibit
Index
|
Exhibit
No.
|
Exhibit
|
|
|
99.1
|
Enzon
Pharmaceuticals, Inc. press release, dated November 9,
2009.
|